Wijesiriwardena, B., 2009. Long acting beta₂ agonists: are they safe?. Ceylon Medical Journal, 51(4), pp.129–131. DOI: http://doi.org/10.4038/cmj.v51i4.1140

Wijesiriwardena B. Long acting beta₂ agonists: are they safe?. Ceylon Medical Journal. 2009;51(4):129–31. DOI: http://doi.org/10.4038/cmj.v51i4.1140

Wijesiriwardena, B. (2009). Long acting beta₂ agonists: are they safe?. Ceylon Medical Journal, 51(4), 129–131. DOI: http://doi.org/10.4038/cmj.v51i4.1140

1. Wijesiriwardena B. Long acting beta₂ agonists: are they safe?. Ceylon Medical Journal. 2009;51(4):129-131. DOI: http://doi.org/10.4038/cmj.v51i4.1140

Wijesiriwardena B, ‘Long Acting Beta₂ Agonists: Are They Safe?’ (2009) 51 Ceylon Medical Journal 129 DOI: http://doi.org/10.4038/cmj.v51i4.1140

Wijesiriwardena, Bandula. 2009. “Long Acting Beta₂ Agonists: Are They Safe?”. Ceylon Medical Journal 51 (4): 129–31. DOI: http://doi.org/10.4038/cmj.v51i4.1140

Wijesiriwardena, Bandula. “Long Acting Beta₂ Agonists: Are They Safe?”. Ceylon Medical Journal 51, no. 4 (2009): 129–31. DOI: http://doi.org/10.4038/cmj.v51i4.1140

Wijesiriwardena, B. “Long acting beta₂ agonists: are they safe?”. Ceylon Medical Journal, vol. 51, no. 4, 2009, pp. 129–31. DOI: http://doi.org/10.4038/cmj.v51i4.1140